Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Mehr anzeigen
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON...
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the...
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.63 | 1.58410862459 | 39.77 | 44.01 | 39.37 | 407117 | 40.95814795 | CS |
| 4 | -7.57 | -15.7806962685 | 47.97 | 50.56 | 36.48 | 558259 | 40.88031808 | CS |
| 12 | -23.1 | -36.3779527559 | 63.5 | 63.5 | 36.48 | 515290 | 45.03584706 | CS |
| 26 | -0.49 | -1.19833700171 | 40.89 | 63.5 | 36.48 | 447739 | 48.62874347 | CS |
| 52 | 6.2 | 18.1286549708 | 34.2 | 72.29 | 33.14 | 512934 | 50.70127057 | CS |
| 156 | 18.9 | 87.9069767442 | 21.5 | 72.29 | 14.19 | 447158 | 43.2016761 | CS |
| 260 | 18.9 | 87.9069767442 | 21.5 | 72.29 | 14.19 | 447158 | 43.2016761 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
